- Home
- RAND vs QNCX Comparison
RAND vs QNCX Comparison
Compare RAND & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RAND
- QNCX
- Stock Information
- Founded
- RAND 1969
- QNCX 2012
- Country
- RAND United States
- QNCX United States
- Employees
- RAND N/A
- QNCX N/A
- Industry
- RAND Finance: Consumer Services
- QNCX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RAND Finance
- QNCX Health Care
- Exchange
- RAND Nasdaq
- QNCX Nasdaq
- Market Cap
- RAND 52.9M
- QNCX 44.0M
- IPO Year
- RAND N/A
- QNCX 2019
- Fundamental
- Price
- RAND $18.22
- QNCX $1.02
- Analyst Decision
- RAND
- QNCX Strong Buy
- Analyst Count
- RAND 0
- QNCX 5
- Target Price
- RAND N/A
- QNCX $8.00
- AVG Volume (30 Days)
- RAND 5.4K
- QNCX 505.9K
- Earning Date
- RAND 05-05-2025
- QNCX 05-16-2025
- Dividend Yield
- RAND 6.37%
- QNCX N/A
- EPS Growth
- RAND 39.63
- QNCX N/A
- EPS
- RAND 3.11
- QNCX N/A
- Revenue
- RAND $8,499,970.00
- QNCX N/A
- Revenue This Year
- RAND N/A
- QNCX N/A
- Revenue Next Year
- RAND N/A
- QNCX N/A
- P/E Ratio
- RAND $5.86
- QNCX N/A
- Revenue Growth
- RAND 12.52
- QNCX N/A
- 52 Week Low
- RAND $13.94
- QNCX $0.51
- 52 Week High
- RAND $31.89
- QNCX $2.45
- Technical
- Relative Strength Index (RSI)
- RAND 42.12
- QNCX 37.79
- Support Level
- RAND $18.00
- QNCX $0.98
- Resistance Level
- RAND $19.70
- QNCX $1.16
- Average True Range (ATR)
- RAND 0.79
- QNCX 0.09
- MACD
- RAND -0.02
- QNCX 0.00
- Stochastic Oscillator
- RAND 7.46
- QNCX 18.52
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.